ArticleJAMA2023
Immunotherapy for Nasopharyngeal Carcinoma: The Earlier the Better.
Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Efficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.British journal of cancer · 2025Pooled it
- Efficacy and safety of toripalimab in the treatment of nasopharyngeal carcinoma: a meta-analysis of single-arm trials.BMC immunology · 2025Pooled it
- Review
- MiR-138-5p Suppresses Glucose Metabolism to Inhibit the Progression of Nasopharyngeal Carcinoma by Targeting the CENPN/PI3K/Akt/mTOR Signaling.Journal of biochemical and molecular toxicology · 2026Article
- VK-2019 enhances gemcitabine's antitumor activity in EBV-positive nasopharyngeal carcinoma by upregulating PRODH expression.Cell death discovery · 2026Article
- Pediatric Nasopharyngeal Carcinoma (NPC).Current oncology reports · 2026Review
- Interpretable AI for treatment decision-making in immunoradiotherapy of locally advanced nasopharyngeal carcinoma.Frontiers in oncology · 2026Article
- Prognostic factors and treatment outcomes in nasopharyngeal carcinoma patients with liver metastasis.American journal of translational research · 2026Article
- New insights into the treatment of nasopharyngeal carcinoma in children, adolescents, and young adults: a retrospective study.Frontiers in immunology · 2026Article
- Discontinuation of immunotherapy and its effect on prognosis in recurrent or metastatic nasopharyngeal carcinoma patients: a retrospective analysis.Cancer immunology, immunotherapy : CII · 2025Article
- Prediction of the disease burden of nasopharyngeal carcinoma in China: A comparative analysis of ARIMA, LSTM, and DNN models.Medicine · 2025Article
- Fertility, gonadal and sexual function in survivors of nasopharyngeal carcinoma patients.BMC cancer · 2025Article
- Extracellular vesicles derived EBV tegument protein BRRF2 suppresses cGAS phase separation to promote anti-viral innate immune evasion.Nature communications · 2025Article
- Nasogastric tube nutrition support enhances chemoradiotherapy compliance and alleviates mucosal reactions in nasopharyngeal carcinoma: a 856-case retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Integrated network pharmacology, molecular docking and experimental validation to investigate the mechanism of tannic acid in nasopharyngeal cancer.Scientific reports · 2025Article
- Specific Immune Responses and Oncolytic Effects Induced by EBV LMP2A-Armed Modified Ankara-Vaccinia Virus Vectored Vaccines in Nasopharyngeal Cancer.Pharmaceutics · 2025Article
- Network pharmacology mechanisms and experimental verification ofFrontiers in oncology · 2025Article
- Targeted Nanoparticle-Based Therapies for Nasopharyngeal Carcinoma: Enhancing Radiosensitization, Photothermal Therapy, and Diagnostics.International journal of nanomedicine · 2025Review
- Article
- Exploring cellular diversity in lung adenocarcinoma epithelium: Advancing prognostic methods and immunotherapeutic strategies.Cell proliferation · 2024Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.